Slide 1: Investor Presentation April 2018
For personal use only INVESTOR PRESENTATION APRIL 2018
Slide 2: Disclaimer
DISCLAIMER This investor presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 Investment risk 949 739) (Cann) and comprises written material regarding Cann. An investment in Cann shares is subject to known and unknown risks, some of which are beyond the control of Cann. Ca
Slide 3: Disclaimer
DISCLAIMER Past performance All rights reserved Investors should note that past performance, including any pro forma historical information in this Several photographs contained in this Presentation are the property of Cann and are protected Presentation, is given for illustrative purposes only and
Slide 4: A substantial & rapidly growing global market
A substantial & rapidly growing global market For personal use only Legal or essentially legal Illegal but decriminalised Illegal but often unenforced Illegal No information • Medicinal cannabis legalised (or decriminalised) in 26 (58) countries across North & South America, Europe & Australia • Glo
Slide 5: Australia – a quickly evolving market
Australia – a quickly evolving market 5 For personal use only REGULATORY STATUS Australia is a potential $1b pa local industry based on an • Access legalised in 2017 estimated 1.2% of the • Jan 2018 – Legislation passed allowing population using cannabis for export of medicinal cannabis medicinal pu
Slide 6: The Export Opportunity
THE EXPORT OPPORTUNITY 6 There is a significant export market opportunity for quality approved Australian medicinal cannabis For personal use only The Canadian Opportunity – demand expected to European medicinal cannabis opportunities outpace supply1 • Canada is providing the “lead” from both a regu
Slide 7: Cann Group is an industry leader in Australia
CANN GROUP IS AN INDUSTRY LEADER IN AUSTRALIA 7 For personal use only • First Australian recipient of research & medicinal cannabis cultivation licences; only company to have licences reissued for year two • Permits granted for two cultivation & R&D facilities currently operational in Victoria – Sou
Slide 8: Strategic Investor: Aurora Cannabis Inc.
STRATEGIC INVESTOR: AURORA CANNABIS INC. 8 One of Canada’s largest publicly-listed cannabis companies, Aurora (TSXV:ACB) For personal use only holds a 22.9% strategic shareholding in Cann •Developing one of the largest production footprints with a purpose-built, state-of-the-art production facility
Slide 9: Business Model & the Industry Value Chain
BUSINESS MODEL & THE INDUSTRY VALUE CHAIN 9 For personal use only FEDERAL & STATE GOVERNMENT REGULATED …with a clear pathway to secure Cann’s competitive strengths lie in these segments of the value chain… involvement in these segments Clinical Cultivation & Packaging & Research & Development Manufa
Slide 10: Growth Strategy
GROWTH STRATEGY 10 For personal use only Cann is well progressed with its three phase growth strategy to substantially expand its cultivation capability, with funding in place to complete Phase 3 Southern facility’s Northern facility secured three additional indoor & commissioned – Greenfield facili
Slide 11: R&D & IP
R&D & IP 11 For personal use only Various images from propagation, cultivation & harvest at Cann’s • Building IP portfolio with R&D program focused on Southern facility variety & cannabinoid profile development • Wisp® vapouriser system development program • CSIRO research program • Accelerated Phas
Slide 12: Upcoming Milestones
UPCOMING MILESTONES 1 2 For personal use only Commissioning of Phase 3 facility Clinical trial involvement 2019 Product available for export Tissue culture quarantine clearance Imported oil available for SAS prescription Site selection of Phase 3 facility 2018
Slide 13: Board & Management Team
BOARD & MANAGEMENT TEAM The team has deep experience in the Australian & Canadian agribusiness, 1 3 biotech & pharma sectors, along with proven entrepreneurial & business development expertise For personal use only • Allan has extensive experience in the agribusiness • Experienced public company dir
Slide 14: Contacts
CONTACTS For personal use only Peter Crock INVESTOR / MEDIA RELATIONS CEO Matthew Wright Cann Group Limited NWR Communications Pty Ltd Ph: +61 (0)3 9095 7088 Ph: +61 (0)451 896 420 E: contact@canngrouplimited.com E: matt@nwrcommunications.com.au
Slide 15: Appendix
For personal use only Appendix 5 1
Slide 16: Capital Structure
CAPITAL STRUCTURE 1 6 For personal use only Since listing on the ASX in May 2017 at an IPO of $0.30 per share, Cann’s share price has performed strongly & rewarded its investors METRIC VALUE Share trading volume and closing price Share price $2.62 8 $4.50 Millions 7 $4.00 $3.50 Shares on issue (full
Slide 17: Australian Regulatory Environment
AUSTRALIAN REGULATORY ENVIRONMENT 1 7 For personal use only • Federal government – UN Single Convention on Narcotic Drugs • Licences – research, cultivation, manufacturing – import/export • Permits – granted only if end use for the plant material is established • State governments • (Schedule 8) mov
Slide 18: Medical Access in Australia
MEDICAL ACCESS IN AUSTRALIA 1 8 For personal use only • Current methods of accessing medicinal cannabis in Australia: - Special Access Scheme – provides for the import/supply of an unapproved therapeutic good for a single patient, on a case-by-case basis - Authorised Prescriber Scheme – enables medi
Slide 19: Growth Cycle & Technology Development
GROWTH CYCLE & TECHNOLOGY DEVELOPMENT 1 9 For personal use only 18-24 hours light per day Less than 12 hours light per day 6-9 week duration Cuttings every two weeks Mother plants Flowering Propagation Vegetative Re-pot 10-14 days 21-28 days Re-pot
Slide 20: For personal use only
srsonal use only. ‘NY =Ok CANN